With CHF20 million (£12.4 million) under its belt from two new financings, Liechtenstein-based Pantec Biosolutions is gearing up for two Phase II clinical trials with hormone-based IVF therapies, to be delivered using transdermal patches in conjunction with the company's PLEASE (Painless Laser EpidermAl System) technology.
The series B financing was led by StemCell Holding, an Austrian venture capital company focused on the biomedical and high-technology...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?